Shakeel Modak, MD
Pediatric Hematologist-Oncologist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Pediatric Hematology-Oncology
- Immunotherapy
- Neuroblastoma
Request an Appointment
About Me
- Chief, Neuroblastoma Service
I am a pediatric oncologist who specializes in caring for children and young adults with neuroblastoma and other solid tumors, such as desmoplastic small round cell tumors. These are challenging cancers to treat. By caring for patients and conducting research, I hope to improve the lives of people diagnosed with these diseases.
Memorial Sloan Kettering treats one of the largest volumes of people with neuroblastoma in the world, giving us a wealth of knowledge and depth of expertise. As Chief of the Neuroblastoma Service, I lead a large multidisciplinary team dedicated to this rare, aggressive cancer in young children. We evaluate each patient and design a personalized care plan.
Read more
I am inspired by the parents of my patients, who work tirelessly to support each other and to raise funds for research. They are vital members of our team and key contributors to our efforts.
With my colleagues, I take the findings of laboratory research and apply them to create new immunotherapies that can target these tumors. Immunotherapies boost the power of the immune system against cancer. We are evaluating radiolabeled monoclonal antibody treatments (a radioactive substance attached to a protein that binds to cancer cells), antibody and cell-based therapies (which recruit immune cells to fight cancer), and anticancer vaccines (which actively train the immune system to fight cancer). These treatments may be more effective when combined with conventional therapies. Pioneering research done by MSK scientists has defined the standards of care used to treat neuroblastoma today.
I also served as chair of the department’s quality assessment committee for many years. In this role, I directed the development and implementation of dozens of strategies, changes, and enhancements to continuously improve patient safety and satisfaction.
In addition to caring for patients and conducting research, I teach and mentor fellows. I am able to provide them with a unique viewpoint on rare diseases that they may not see at other institutions. It is gratifying for me to see them make their own contributions to our field.
A pediatric hematologist-oncologist is a doctor who treats cancers of the blood in children and adolescents. This doctor is a hematologist (HEE-muh-TAH-loh-jist) who diagnoses and treats blood disorders. They also are an oncologist (cancer doctor).
My Specialties
- Pediatric Hematology-Oncology
- Immunotherapy
- Neuroblastoma
Education
- MD, Topiwala National Medical College
Residencies
- Pediatrics - BYL Nair Charitable Hospital
- Pediatric Infectious Disease - Kasturba Hospital
- Pediatrics - Farnborough Hospital
- Pediatric Hematology - Birmingham Children's Hospital
- Neonatology - Whittington Hospital
- Pediatric Oncology - Royal Marsden Hospital
- Pediatrics - Blank Children's Hospital
Awards and Honors
- Castle Connolly: Top AAPI Doctor (2024)
- Castle Connolly: America’s Top Doctor (2024)
- Top Doctors New York Metro Area, Castle Connolly (2023)
- Castle Connolly: America's Top Doctors (2023)
- Castle Connolly: New York Magazine Top Doctors (2014, 2016-2020)
Fellowships
- Pediatric Hematology/Oncology - Memorial Sloan Kettering Cancer Center
Board Certifications
- Pediatric Hematology-Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
New Patients
Current Patients
Contact and Location
Dr. Modak sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Co-Investigated by Dr. Modak
- A Phase II Study of 131I-MIBG Alone or with Vorinostat in People with High-Risk Neuroblastoma
- A Pilot Phase II Study of Targeted Radiotherapy with 131I-MIBG and Arsenic Trioxide in Patients with Resistant Neuroblastoma or Malignant Chromaffin Cell Tumors
- A Pilot Study of Shortened Induction Chemotherapy for Children with High-Risk Neuroblastoma
- Molecular Characterization of Neuroblastic Tumors and Clinical Outcome
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Modak’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Shakeel Modak discloses the following relationships and financial interests:
-
Innervate Radiopharmaceuticals LLC
Professional Services and Activities -
Kymera Therapeutics, Inc.
Professional Services and Activities
-
SciClone Pharmaceuticals International, Ltd.
Professional Services and Activities -
Y-mAbs Therapeutics, Inc.
Intellectual Property Rights
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].